GLP-1 Drugs Reduce Seizure and Epilepsy Risk by 24% According to Meta-Analysis of 200,000 Patients

GLP-1 receptor agonists reduced the risk of late-onset seizures and epilepsy by 24% (RR: 0.76, 95% CI: 0.62-0.95) in a meta-analysis of 27 RCTs with ~200,000 patients. The benefit was specific to GLP-1 RAs, not DPP-4i or SGLT2i.

Meta-analysis of 27 randomized controlled trials from MEDLINE and CENTRAL databases comparing newer glucose-lowering drugs (DPP-4i, GLP-1 RAs, SGLT2i) to placebo. Assessed seizure and epilepsy as adverse events. Calculated RR using Mantel-Haenszel method and OR using Peto's method. Mean age 64.9 years, 65.6% male.

Late-onset epilepsy is a growing concern in aging populations. Finding that widely prescribed GLP-1 drugs also protect against seizures could be clinically significant for millions of diabetic patients, and raises the possibility of repurposing these drugs for epilepsy prevention in high-risk groups.

This adds epilepsy prevention to the growing list of non-metabolic benefits attributed to GLP-1 receptor agonists, alongside cardiovascular protection, neuroprotection, and potential kidney benefits. The anti-epileptogenic effect appears independent of stroke reduction, suggesting a direct neuroprotective mechanism.

Seizures and epilepsy were captured as adverse events in cardiovascular/renal outcome trials, not as primary endpoints — potentially underreported. The mechanism (anti-inflammatory, neuroprotective, or other) is not established. The patient population was primarily older adults with type 2 diabetes — generalizability to non-diabetic populations is unknown.